secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-115958
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX closes public offering of ~47M shares/warrants, net proceeds ~$234.4M for pipeline
--------------------------------------------------------------------------------

- Sold 45,990,567 shares at $5.30 and pre-funded warrants for 1,179,245 shares at $5.29999 each.
- Underwriters granted 30-day option to purchase up to 7,075,471 additional shares at the offering price.
- Net proceeds estimated at approximately $234.4 million after underwriting discounts and expenses.
- Proceeds to fund continued development of Varseta-M and other pipeline programs, plus general corporate purposes.
- Offering closed on March 19, 2026 under an underwriting agreement dated March 17, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526115958/0001193125-26-115958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526115958/d100765d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-115958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer